Glioblastoma Multiforme (GBM) is one of the most lethal cancers with a median survival of 15 months despite surgery, radiation, and chemotherapy. Hence there is a desperate need for new treatments. One strategy involves targeting both glioblastoma cells and other immune cells that interact with the tumor. These immune cells…
A New Study Identifies Novel Druggable Targets in Glioblastoma

Recent Comments